426 related articles for article (PubMed ID: 21250818)
41. Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3Kα inhibitors.
Wu P; Su Y; Liu X; Zhang L; Ye Y; Xu J; Weng S; Li Y; Liu T; Huang S; Yang B; He Q; Hu Y
Eur J Med Chem; 2011 Nov; 46(11):5540-8. PubMed ID: 21945250
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and antitumor activity of new retinobenzoic acids.
Khandare RP; Vaze KR; Bhat SV
Chem Biodivers; 2011 May; 8(5):841-9. PubMed ID: 21560232
[TBL] [Abstract][Full Text] [Related]
43. 5-Substituted [1]pyrindine derivatives with antiproliferative activity.
Kolb S; Goddard ML; Loukaci A; Mondésert O; Ducommun B; Braud E; Garbay C
Eur J Med Chem; 2010 Mar; 45(3):896-901. PubMed ID: 19969400
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and cytotoxicity of 2-methyl-4, 9-dihydro-1-substituted-1H-imidazo[4,5-g]quinoxaline-4,9-diones and 2,3-disubstituted-5,10-pyrazino[2,3-g]quinoxalinediones.
Yoo HW; Suh ME; Park SW
J Med Chem; 1998 Nov; 41(24):4716-22. PubMed ID: 9822542
[TBL] [Abstract][Full Text] [Related]
45. Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach.
Kaneko D; Ninomiya M; Yoshikawa R; Ono Y; Sonawane AD; Tanaka K; Nishina A; Koketsu M
Bioorg Chem; 2020 Nov; 104():104293. PubMed ID: 33010622
[TBL] [Abstract][Full Text] [Related]
46. Quinoxaline chemistry. Part 5. 2-(R)-benzylaminoquinoxalines as nonclassical antifolate agents. Synthesis and evaluation of in vitro anticancer activity.
Loriga M; Fiore M; Sanna P; Paglietti G
Farmaco; 1996; 51(8-9):559-68. PubMed ID: 8930109
[TBL] [Abstract][Full Text] [Related]
47. New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents.
Ismail MM; Amin KM; Noaman E; Soliman DH; Ammar YA
Eur J Med Chem; 2010 Jul; 45(7):2733-8. PubMed ID: 20236735
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and biological evaluation of novel 6-hydrazinyl-2,4-bismorpholino pyrimidine and 1,3,5-triazine derivatives as potential antitumor agents.
Zhu W; Liu Y; Zhao Y; Wang H; Tan L; Fan W; Gong P
Arch Pharm (Weinheim); 2012 Oct; 345(10):812-21. PubMed ID: 22707438
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors.
Ye Q; Cao J; Zhou X; Lv D; He Q; Yang B; Hu Y
Bioorg Med Chem; 2009 Jul; 17(13):4763-72. PubMed ID: 19447039
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents.
Li W; Zhai X; Zhong Z; Li G; Pu Y; Gong P
Arch Pharm (Weinheim); 2011 Jun; 344(6):349-57. PubMed ID: 21433057
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and anti-breast cancer activity of new indolylquinone derivatives.
Li X; Zheng SL; Li X; Li JL; Qiang O; Liu R; He L
Eur J Med Chem; 2012 Aug; 54():42-8. PubMed ID: 22658083
[TBL] [Abstract][Full Text] [Related]
52. Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.
Galal SA; Abdelsamie AS; Tokuda H; Suzuki N; Lida A; Elhefnawi MM; Ramadan RA; Atta MH; El Diwani HI
Eur J Med Chem; 2011 Jan; 46(1):327-40. PubMed ID: 21145626
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives.
Zheng M; Xu C; Ma J; Sun Y; Du F; Liu H; Lin L; Li C; Ding J; Chen K; Jiang H
Bioorg Med Chem; 2007 Feb; 15(4):1815-27. PubMed ID: 17157510
[TBL] [Abstract][Full Text] [Related]
54. Synthesis, antiproliferative activities and in vitro biological evaluation of novel benzofuransulfonamide derivatives.
Yang L; Lei H; Mi CG; Liu H; Zhou T; Zhao YL; Lai XY; Li ZC; Song H; Huang WC
Bioorg Med Chem Lett; 2011 Sep; 21(18):5389-92. PubMed ID: 21795045
[TBL] [Abstract][Full Text] [Related]
55. Investigation of Isoindolo[2,1-a]quinoxaline-6-imines as Topoisomerase I Inhibitors with Molecular Modeling Methods.
Balogh B; Carbone A; Spanò V; Montalbano A; Barraja P; Cascioferro S; Diana P; Parrino B
Curr Comput Aided Drug Des; 2017; 13(3):208-221. PubMed ID: 28120705
[TBL] [Abstract][Full Text] [Related]
56. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.
El Newahie AM; Ismail NS; Abou El Ella DA; Abouzid KA
Arch Pharm (Weinheim); 2016 May; 349(5):309-26. PubMed ID: 27062086
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and in vitro cytotoxicity evaluation of novel naphthindolizinedione derivatives.
Defant A; Guella G; Mancini I
Arch Pharm (Weinheim); 2007 Mar; 340(3):147-53. PubMed ID: 17315260
[TBL] [Abstract][Full Text] [Related]
58. Design and Synthesis of New Quinoxaline Derivatives as Anticancer Agents and Apoptotic Inducers.
El Newahie AMS; Nissan YM; Ismail NSM; Abou El Ella DA; Khojah SM; Abouzid KAM
Molecules; 2019 Mar; 24(6):. PubMed ID: 30934622
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and cytotoxic activities of 8-alkyl or 8-aryl-8,9-dihydro-7H-isoindolo[5,6-g]quinoxaline-7,9-diones.
Jung JK; Jung EK; Nam-Goong K; Cho JS; Kim HM; Park SG; Yoo YA; Kwon JH; Lee HS
Arch Pharm Res; 2006 Apr; 29(4):276-81. PubMed ID: 16681031
[TBL] [Abstract][Full Text] [Related]
60. Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: novel, hypoxia-selective HIF-1α inhibitors with strong antiestrogenic potency.
Buravchenko GI; Scherbakov AM; Dezhenkova LG; Bykov EE; Solovieva SE; Korlukov AA; Sorokin DV; Monzote Fidalgo L; Shchekotikhin AE
Bioorg Chem; 2020 Nov; 104():104324. PubMed ID: 33142432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
